

Application No. 10/023,437  
Reply to Office Action of June 29, 2007  
Amendment Dated August 8, 2007

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-91 (canceled)

Claim 92 (previously presented): A method of immunizing an animal comprising the step of:

administering a Chlamydia psittaci antigen to an animal in an amount effective to induce an immune response against Chlamydia psittaci; wherein the Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO:9.

Claim 93 (previously presented): The method of claim 92, wherein the Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO:7.

Claim 94 (previously presented): The method of claim 92, wherein the method further comprises the step of:

administering a second Chlamydia psittaci antigen to an animal in an amount effective to induce an immune response against Chlamydia psittaci; wherein the second Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO: 7, 11, 13, 17, 23, or 27.

Claim 95 (previously presented): The method of claim 93, wherein the method further comprises the step of:

administering a second Chlamydia psittaci antigen to an animal in an amount effective to induce an immune response against Chlamydia psittaci; wherein the

Application No. 10/023,437  
Reply to Office Action of June 29, 2007  
Amendment Dated August 8, 2007

second Chlamydia psittaci antigen comprises the amino acid sequence as set forth as SEQ ID NO: 11, 13, 17, 23 or 27.

Claims 96-103 (canceled)

Claim 104 (previously presented): The method of claim 92 wherein the step of preparing a Chlamydia psittaci antigen further comprises preparing the Chlamydia psittaci antigen in a pharmaceutically acceptable carrier.

Claim 105 (previously presented): The method of claim 94 wherein the steps of preparing a Chlamydia psittaci antigen and preparing a second Chlamydia psittaci antigen further comprises preparing the Chlamydia psittaci antigen and the second Chlamydia psittaci antigen in a pharmaceutically acceptable carrier.

Claim 106 (previously presented): The method of claim 95 wherein the steps of preparing a Chlamydia psittaci antigen and preparing a second Chlamydia psittaci antigen further comprises preparing the Chlamydia psittaci antigen and the second Chlamydia psittaci antigen in a pharmaceutically acceptable carrier.

Claim 107 (previously presented): The method of claim 92 wherein the animal is a bovine.

Claim 108 (previously presented): The method of claim 94 wherein the animal is a bovine.

Claim 109 (previously presented): The method of claim 95 wherein the animal is a bovine.

Claim 110 (previously presented): The method of claim 92 wherein the animal is a human.

Claim 111 (previously presented): The method of claim 94 wherein the animal is a human.

Claim 112 (previously presented): The method of claim 95 wherein the animal is a human.

Claim 113 (previously presented): The method of claim 92 wherein the animal is a mammal.

Claim 114 (previously presented): The method of claim 94 wherein the animal is a mammal.

Claim 115 (previously presented): The method of claim 95 wherein the animal is a mammal.

Claim 116 (previously presented): The method of claim 94 wherein the step of administering the second Chlamydia psittaci antigen comprises administering the second antigen simultaneously with the administration of the first antigen.

Claim 117 (previously presented): The method of claim 94 wherein the step of administering the second Chlamydia psittaci antigen comprises administering the second antigen subsequent to the administration of the first antigen.

Claim 118 (previously presented): The method of claim 94 wherein the step of administering the second Chlamydia psittaci antigen comprises administering the second antigen prior to administration of the first antigen.

Application No. 10/023,437  
Reply to Office Action of June 29, 2007  
Amendment Dated August 8, 2007

Claim 119 (previously presented): The method of claim 95 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen simultaneously with the administration of the first antigen.

Claim 120 (previously presented): The method of claim 95 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen subsequent to the administration of the first antigen.

Claim 121 (previously presented): The method of claim 95 wherein the step of administering the second *Chlamydia psittaci* antigen comprises administering the second antigen prior to administration of the first antigen.